Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of LY3015014 in primary hypercholesterolemia
jRCT2080222170Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of frovocimab in hypercholesterolemia (3 arms), sponsored by Eli Lilly and Company.
02
Drugs
frovocimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on jRCT2080222170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222170.